June 24th 2025
mRNA technologies offer great promise in immunotherapy and non-immunogenic applications.
May 7th 2025
FDA chooses Dr. Vinay Prasad, MD, MPH, a hematologist-oncologist, to lead the Center for Biologics Evaluation and Research at FDA.
March 25th 2025
Under the agreement, AstraZeneca will use Alteogen’s proprietary hyaluronidase platform technology to develop and commercialize subcutaneous formulations of multiple oncology assets in its portfolio.
February 17th 2025
The approval makes Evrysdi the first and only tablet for treating spinal muscular atrophy.
February 8th 2025
European biopharma companies are looking beyond GLP-1s.
Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.
Aprecia Expands Capacity for 3D-Printed Dosage Manufacturing
Aprecia Pharmaceuticals' new facility in Ohio will create 150 jobs.
BMS Furthers its Immuno-Oncology Pipeline with Nearly $1.6 Billion in Investments
Bristol-Myers Squibb announced that it reached an agreement to acquire Flexus Biosciences and has entered into a $309-million partnership with Rigel Pharmaceuticals.
Celltrion Announces that Remicade Biosimilar Could Save Up to $380 Million USD
Celltrion announced that its Remicade biosimilar, Rensima, could save France, Italy, and the UK up to €336 million in costs to treat Crohn’s disease.
Cell Medica Begins Commercial Manufacturing of Cell Therapies
The Berlin-Buch facility will begin manufacture of the company’s immune cell therapy.
Single-use Purification Media Improves Efficiency
The all-synthetic 3M Emphaze AEX Hybrid Purifier contains both an anion-exchange nonwoven media and a fine-particle, bioburden reduction membrane.
Rotary Capsule Filler Reduces Product Loss
MG America's TEKNA Capsule Filler has advanced controls to reduce powder loss and maintain optimal performance.
First Hospira Biosimilar mAb Approved in West Europe
Hospira’s Inflectra (infliximab), a biosimilar for Remicade, is approved by the European Commission.
New Financial Strategies Needed to Support Biomedical Innovation
The ongoing battle over drug reimbursement and pricing has raised questions about whether the pharmaceutical industry can continue to rely on high United States revenues to fund biopharmaceutical R&D.
CDER and Biotech Quality Assessment
The Center for Drug Evaluation and Research seeks a more flexible system for assessing biotech product quality.
Pfenex Announces Partnership with Hospira to Develop Lucentis Biosimilar
Pfenex announced that it entered into an agreement to partner with Hospira on the development and commercialization of PF582, a biosimilar candidate to Lucentis.
Amgen Announces Humira Biosimilar Clinical Studies Success
Amgen announced that it met primary and secondary endpoints in its biosimilar evaluation of adalimumab for the treatment of rheumatoid arthritis, when compared to Humira.
First Inhalable Insulin Comes to the US
Sanofi launched a rapidly absorbed, short-acting inhalable insulin in the US to help control type 1 and type 2 diabetes.
Mylan Partners with Theravance to Develop an Investigational Treatment for COPD
Mylan announced a partnership with Theravance Biopharma to develop and commercialize TD-4208, a novel investigational COPD treatment.
Obama Seeks Drug Pricing Authority, Shortened Data Exclusivity Period for Biologics
The 2016 White House Budget proposes a change to the data exclusivity period for biologics and the authority to influence drug pricing.
Preventing Tablet Tooling Problems
Tooling can be damaged by poor handling or problems in process design or material choice.
Ligand-Binding Assays and the Determination of Biosimilarity
Ligand-binding assays are fundamental to characterizing biosimilars.
Labeling of Biosimilars
EMA is under pressure to exert even tighter standards on biosimilars being marketed in Europe.
Gauging the CMO Biosimilar Opportunity
Market forces may limit the success of CMOs.
Developing and Validating Assays for Small-Molecule Biomarkers
Working with biological matrices and understanding the intended use are crucial.
Special Considerations for Extractables and Leachables Testing in Biological Products
New guidelines focused on the materials of construction in biologic therapy packaging will help vendors prepare comprehensive extractable and leachable testing strategies.
The Future of Contract Services
CMO executives share their opinions on where outsourcing is going and what is driving market change.
FUJIFILM's New Biopharm Game Plan
After launching a new mammalian cell platform, FUJIFILM Diosynth Biotechnologies U.S.A., has acquired fast-track vaccine manufacturing knowhow and a major presence in Texas’ emerging biocorridor with Kalon, its first acquisition.
Catalent Expands High-Potency Handling Capability
Catalent will add potent containment for blending and granulation at its New Jersey manufacturing Center of Excellence.
Ebola Treatments Ramp Up for Clinical Trials
Government and industry efforts to address manufacturing challenges move Ebola vaccine candidates into larger clinical trials.
CDC Publishes Information on Reducing Worker Exposure to Hazardous Drugs
A draft NIOSH Current Intelligence Bulletin on recommendations for reducing worker exposure to reproductive risks of drugs is available for public comment.
Filling Pre-sterilized Containers
Pre-sterilized, nested syringes and vials are seeing increased use in sterile filling.
Catalent and MGC Pharma Partner for Production of Cell Lines
Catalent announced that it would partner with Mitsubishi Gas Chemical Company, and its subsidiary MGC Pharma, to promote GPEx technology, a high-titer vector for stable mammalian cell lines.
Sanofi Forms Strategic Pact with Boehringer Ingelheim for Biologics Manufacture
Sanofi has entered into a strategic manufacturing collaboration with Boehringer Ingelheim for the manufacture of therapeutic monoclonal antibodies (mAbs).
Catalent and Sanofi to Collaborate on ADC Development
Catalent Pharma Solutions and Sanofi-Aventis R&D have entered into a collaboration to develop Sanofi’s proprietary antibodies using Catalent’s SMARTag antibody drug conjugate (ADC) platform.
FDA Advisors Unanimously Approve Sandoz Biosimilar
An FDA expert committee has recommend approval of Zarizio, the first US biosimilar application from Sandoz, setting a milestone for generic biologic drugs and setting the stage for future approvals.